Related Experiment Videos
Distinctive properties of perindopril among converting enzyme inhibitors in congestive heart failure
1Department of Medicine, McGill University, Montreal, Quebec.
Insights
Perindopril, a novel angiotensin-converting enzyme (ACE) inhibitor, offers sustained ACE inhibition for congestive heart failure (CHF) patients. It improves hemodynamics and survival without the hypotension or renal issues common with other ACE inhibitors.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are crucial for managing congestive heart failure (CHF), improving hemodynamics and survival.
- Some CHF patients experience intolerance to conventional ACE inhibitors due to side effects like hypotension and renal dysfunction.
Purpose of the Study:
- To evaluate the efficacy and tolerability of perindopril, a third-generation ACE inhibitor, in patients with CHF.
Main Methods:
- Assessing the pharmacokinetic profile of perindopril, focusing on the duration of ACE inhibition.
- Monitoring hemodynamic parameters, survival rates, and renal function (serum creatinine and urea) in CHF patients treated with perindopril.
- Comparing perindopril's effects with those of other ACE inhibitors like captopril and enalapril.
Main Results:
- Perindopril provides profound and prolonged (24-hour) ACE inhibition after a single dose.
- Unlike captopril and enalapril, perindopril does not cause significant first-dose hypotensive effects.
- Studies indicate stable serum creatinine and urea levels with perindopril, suggesting favorable renal tolerance in CHF patients.
Conclusions:
- Perindopril represents a well-tolerated ACE inhibitor for CHF management, offering sustained efficacy without common adverse effects.
- Its favorable renal profile distinguishes it from other ACE inhibitors, making it a valuable option for CHF patients.
- Perindopril improves hemodynamics and survival while maintaining renal function, addressing limitations of existing therapies.
Abstract:
Converting enzyme inhibitors constitute a major advance in the management of patients with congestive heart failure (CHF). Not only do they improve the hemodynamics of these patients, but they also prolong the survival. Certain patients with CHF, however, may not tolerate conventional converting enzyme inhibitors because of hypotension, renal dysfunction or other side effects. Perindopril is a third generation converting enzyme inhibitor that produces profound and prolonged angiotensin-converting enzyme (ACE) inhibition (24 h after a single dose). Despite a more sustained ACE inhibition than captopril and enalapril, perindopril is devoid of the first dose hypotensive effects noted with these other drugs. Furthermore, several studies of perindopril in CHF showed serum creatinine and urea to remain stable, reflecting favourable renal tolerance. This is in contrast to the modest decrease in renal function observed with most other converting enzyme inhibitors.